Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Terremoto launches with $75 million for covalent molecules

by Michael McCoy
May 26, 2022 | A version of this story appeared in Volume 100, Issue 19

 

Terremoto Biosciences has launched with $75 million in series A financing to discover small-molecule drugs using its lysine-targeted covalency technology. Terremoto says most drugs that bind to targets with covalent bonds attach to cysteine, which is uncommon in proteins. The South San Francisco–based firm says it has made breakthroughs in chemistry and biology allowing it to develop drugs that covalently bind to lysine, which is present in nearly every protein of interest.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.